ADC
ADC
Revolutionary Munich Company Doses First Patient with Groundbreaking Cancer Treatment
BIOT
📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪
J&J Invests $2bn in Game-Changing Cancer Treatments
BIOT
🔍 Johnson & Johnson acquires Ambrx for $2bn to boost its ADC pipeline and advance innovative cancer treatments. 💼🌐💉
Accelerating ADC Development and Manufacturing: Streamlining Solutions
BIOT
📰 ADC Development and Manufacturing: Simplify, Derisk, and Accelerate the Timeline tackles challenges and offers solutions for ADC development and manufacturing. 🧬🔬🎯
